Boothbay Fund Management’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.7M Sell
122,228
-4,847
-4% -$179K 0.06% 337
2025
Q4
$4.51M Sell
127,075
-65,695
-34% -$1.85M 0.07% 320
2025
Q3
$2.77M Sell
192,770
-309,230
-62% -$3.66M 0.04% 488
2025
Q2
$3.6M Buy
+502,000
New +$2.78M 0.07% 368
2022
Q4
Sell
-19,752
Closed -$295K 2059
2022
Q3
$295K Sell
19,752
-13,748
-41% -$188K 0.01% 1547
2022
Q2
$302K Buy
+33,500
New +$229K 0.01% 1458
2021
Q2
Sell
-11,109
Closed -$98K 1888
2021
Q1
$98K Buy
+11,109
New +$107K ﹤0.01% 1474

Other funds holding COGT

Boothbay Fund Management's COGT Position: Q1 2026 in Review

Boothbay Fund Management reduced its Cogent Biosciences (COGT) stake by 3.8% in Q1 2026, selling an estimated $179K and leaving 122,228 shares worth $4.7M. The position accounts for 0.06% of the portfolio, ranked #337.

Boothbay Fund Management first reported a position in COGT in Q1 2021 and has held it in 7 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Boothbay Fund Management held 122,228 shares of Cogent Biosciences worth $4.7M as of Q1 2026.
  • Boothbay Fund Management sold 4,847 Cogent Biosciences shares in Q1 2026, an estimated $179K.
  • Cogent Biosciences made up 0.06% of Boothbay Fund Management's portfolio in Q1 2026, its #337 holding.
  • Boothbay Fund Management first reported a position in Cogent Biosciences in Q1 2021 and has held it in 7 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.